A number of research firms have commented on MDT. Wolfe Research raised Medtronic from an "underperform" rating to a "peer perform" rating in a research note on Monday, June 30th. William Blair raised Medtronic to a "hold" rating in a research note on Friday, July 11th. Truist Financial upped their price target on Medtronic from $92.00 to $96.00 and gave the company a "hold" rating in a research note on Thursday, August 21st. Morgan Stanley reaffirmed an "overweight" rating and set a $107.00 price target (up previously from $98.00) on shares of Medtronic in a research note on Tuesday, July 15th. Finally, Wells Fargo & Company increased their target price on Medtronic from $98.00 to $100.00 and gave the company an "overweight" rating in a research note on Wednesday, August 20th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and eight have given a Hold rating to the stock.